M. Mascia

Journal Pre-proof Primary Radical Prostatectomy or Ablative (RP/EBRT) are Protective Factors in mCRPC Patients Treated With 223Radium-dichloride: An Italian Multicenter Study.

L. Cindolo, A. Spanu, S. Nuvoli, 2019 .

Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223Radium-dichloride: a national multicenter study

L. Cindolo, G. Rubini, A. Spanu, 2020, Annals of Nuclear Medicine.

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study.

A. Farcomeni, L. Cindolo, A. Spanu, 2019, Clinical genitourinary cancer.

A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223

A. Farcomeni, L. Cindolo, G. Rubini, 2020, Aging Clinical and Experimental Research.

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study

S. Fanti, S. Morbelli, G. Sambuceti, 2022, Cancers.

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

A. Farcomeni, L. Cindolo, G. Rubini, 2020, International journal of radiation biology.

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)

G. Sambuceti, L. Cindolo, G. Rubini, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

A. Farcomeni, L. Cindolo, G. Rubini, 2022, Minerva Urology and Nephrology.

Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies

L. Cindolo, M. Marchioni, L. Schips, 2021, Clinical nuclear medicine.